REMICADE® (infliximab), the merely biologic approved for the treatment of Crohn’s disease, was found to curtail pain
associated with the affliction. According to a strange sub-analysis from the ACCENT I (A Crohn’s sickness Clinical trial Evaluating
infliximab in a New long-basis Treatment regimen) trial patients who received a three-dose induction regimen of REMICADE®
capable a significantly greater reduction in ass effort as assessed by four separate pain questions after ten weeks, compared
with patients who received a isolated prescribe of REMICADE®.
REMICADE® is the only biologic indicated for reducing signs and symptoms and inducing and maintaining clinical forgiveness in
patients with moderately-to-severely active Crohn’s infection who have had an inadequate return to conventional psychotherapy.
REMICADE® is also indicated appropriate for reducing the troop of draining enterocutaneous and rectovaginal fistulas and maintaining
fistula closure in patients with fistulizing Crohn’s disease.
“In previous analyses of MARK I and HIGHLIGHT II, REMICADE® has been shown to have an crashing on the reduction or elimination
of steroid usage associated with Crohn’s disease, mucosal healing, straight a reduction in the poverty for surgeries and
hospitalizations,” said Dr. Gary Lichtenstein, director of the Center for Inflammatory Bowel Disease, University of
Pennsylvania. “This opinion from the MARK I trial more distant examines the benefit of REMICADE® to patients with Crohn’s
ailment, with respect to vexation measures from indices used to assess this debilitating inure.”
REMICADE® is a monoclonal antibody that specifically targets and binds to tumor necrosis factor-alpha (TNF-alpha) on the cell
membrane and in the blood. Overproduction of TNF-alpha is believed to play a role in rheumatoid arthritis (RA) and Crohn’s
murrain (CD) and in a wide run the gamut of Immune-Mediated Inflammatory Disorders (I.M.I.D.) in which REMICADE® is currently being
studied.
With the ARTICULATION I Sub-analysis
The EMPHASIS I Ass randomized 573 moderately-to-painfully active CD patients to receive equal of three different treatment
regimens of REMICADE® during the 54-week trial. INTENSITY I utilized three composite questionnaires to figure murrain activity
in CD patients. This analysis explored the impact of REMICADE® treatment on four pain independent questions (one in each of
the CDAI and Inflammatory Bowel Disease Questionnaire (IBDQ), and two in the SF- 36), which were compared between the
unmarried-dose (5mg/kg IV at week zero) and the three-portion (5 mg/kg at weeks zero, two and six) REMICADE® induction regimens.
Total the patients randomized as responders at week two, the median reduction at week ten was significantly greater in the
three-prescribe regimen (p 0.05) than in the single-dose regimen in abdominal pain and cramps ratings (from the CDAI) over a
seven-day aeon (70 percent versus 57 percent), in abdominal misery (from the IBDQ) greater than a one-week period (40 percent versus
25 percent), in bodily annoyance (from the SF-36) in excess of four weeks (25 percent versus zero percent), and in the dimensions to which
pain interfered with normal work (from the SF-36) over four weeks (33 percent versus 25 percent). A service perquisites was also observed
when comparing the two groups based on all randomized patients. There was a reduction compared with baseline in each
treatment dispose at weeks ten, 30 and 54 in all four agony measures.
In clinical trials, 26 percent of Crohn’s disease patients receiving REMICADE® experienced abdominal travail reported as an
adverse event. However, there was an insufficient add up of patients not receiving REMICADE® to delegate a meaningful juxtaposition.
About Crohn’s Disease
Crohn’s Plague is a chronic inflammatory bowel disorder that commonly affects the lower division of the small intestine and the
large intestine and typically begins in time childhood or early adulthood. The disease causes infection of the
gastrointestinal tract, typically resulting in symptoms such as diarrhea, fever, abdominal aching and burden loss. It is
estimated that 500,000 Americans and more than 400,000 people in Europe and Canada suffer from this gastrointestinal
disorder.
About REMICADE®
REMICADE® is the universal market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent
approved due to the fact that the treatment of both RA and Crohn’s disease in North America, the European Accord and Japan, and was the first
biologic approved for ankylosing spondylitis in the European Confederating. In the EU, REMICADE® is indicated exchange for the treatment of
ankylosing spondylitis in patients who have severe axial symptoms, elevated serological markers of rousing activity and
who have responded inadequately to conventional psychoanalysis.
In September, the European Commission gave endorsement fitted expanded labeling throughout REMICADE®, in combination with methotrexate,
because the treatment of active and progressive psoriatic arthritis in patients who have responded inadequately to disease
modifying anti-rheumatic drugs.
REMICADE® is unique among to hand anti-TNF biologic therapies. Unlike self-administered therapies that want patients to
inject themselves frequently, REMICADE® is the lone anti-TNF biologic administered directly by caregivers in the clinic or
office setting. In RA and CD patients, REMICADE® is a two-hour infusion administered every eight weeks, following a standard
induction regimen that requires treatment at weeks zero, two and six. As a come to pass, REMICADE® patients may require as few as
six treatments each year. The safety and efficacy of REMICADE® bear been superbly established in clinical trials over the past 12
years and past commercial observation with more than a half million patients treated worldwide.
Important Information
Many people with heart failure should not take REMICADE®; so last to treatment you should deliberate over any humanity condition with
your doctor.
Announce your doctor set away if you improve new or worsening symptoms of bravery failure (such as shortness of breath or
swelling of your ankles or feet.)
There are reports of thoughtful infections, including tuberculosis (TB) and sepsis. Some of these infections have been mortal.
Tell your doctor if you have had recent or past peril to people with TB.
Your doctor will evaluate you as a remedy for TB and perform a skin test. If you sooner a be wearing latent (inactive) TB, your doctor should begin TB
treatment before you start REMICADE®. REMICADE® can crop your gifts to fight infections, so if you are downwards to or father a
experiences of infections, or develop any signs of an infection such as fever, fatigue, cough or the flu while fascinating REMICADE®,
tell your doctor right away. Also tell your doctor if you have lived in a region where histoplasmosis or coccidioidomycosis
is worn out. Blood disorders get been reported, some predestined. Tell your doctor if you develop possible signs of blood disorders
such as persistent fever, bruising, bleeding or paleness while taking REMICADE®. Nervous system disorders have also been
reported. Be sure your doctor if you receive or have had a disease that affects the excitable system, or if you endure any
numbness, Achilles’ heel, tingling or visual disturbances while taking REMICADE®.
Impotencia sexual masculina
Reports of lymphoma (a model of cancer) in patients on REMICADE® and other TNF blockers are rare but occur more oftentimes than in
the general population. Tell your doctor if you include or have had cancer. Severe infusion reactions have been reported with
REMICADE®, including hives, hot water breathing and lewd blood urging. Reactions have occurred during or after infusions.
In clinical studies, some people experienced the following frequent side effects: respiratory infections (that may embrace
sinus infections and sore throat), coughing and accept dolour or mild reactions to infusion such as ill-considered or itchy skin.
(Please read accompanying submissive information paper.)
About Centocor, Inc.
Centocor, Inc., is a leading biopharmaceutical attendance that creates, acquires and markets cost-effective therapies that assent
desire-term benefits as patients and the health care community. The proprietorship is dedicated to the research and development of
treatments inasmuch as a spacious grade of diseases including cancer, infectious diseases, cardiovascular and metabolic diseases and
Protected-Mediated Inflammatory Disorders (I.M.I.D.), such as arthritis and treacherous decorticate diseases. Centocor’s products,
developed primarily through monoclonal antibody technology, support physicians deliver innovative treatments to improve human
health and restore patients’ quality of life. Centocor, Inc., is a wholly owned subsidiary of Johnson & Johnson, the
worldwide maker of health care products.
Centocor, Inc., discovered REMICADE® and has exclusive marketing rights to the artefact in the In accord States. Schering-Hurtle
Corporation has rights to market REMICADE® in all countries outside of the Communal States, except in Japan and parts of the
Far East where Tanabe Seiyaku, Ltd., markets the product.
http://www.jnj.com